At the IGTP TODAY
DevsHealth, a leading company in artificial intelligence (AI) driven drug discovery, and the Germans Trias i Pujol Research Institute (IGTP), a public research centre in biomedical sciences, have announced a new partnership to develop new antibiotics for multi-resistant Staphylococcus aureus infections.
The Innomed Awards, held at the Can Ruti Campus, celebrated significant advancements in biomedical innovation and reinforced the commitment to collaboration among the leading healthcare and research institutions of this health ecosystem and its surroundings.
IGTP presented yesterday, 10 June, the initiative with a total of 45 companies and entities participating, which will promote the research and development of these medicines to generate an economic and social impact in Catalonia.
CMCiB-IGTP has renewed its certificate of compliance with Good Laboratory Practices (GLP) in accordance with Directive 2004/9/EC.
Researchers from IGTP and Ahead Therapeutics have been exploring a treatment based on liposome-type nanoparticles to address the autoimmunity of type 1 diabetes for years. A study recently published in the Journal of Autoimmunity examines the response of macrophages to this immunotherapy, serving as a preliminary step before clinical trials.
The Innomed programme has been launched with the ambition of transforming the landscape of health innovation at the Can Ruti Campus, creating synergies between the public and private sectors. With a structured approach around three key axes - nurturing the culture of innovation, fostering project incubation, and facilitating cross-sector collaboration - Innomed aims to turn knowledge into action to achieve tangible impact on the healthcare community.
Institutions in and around the Can Ruti Campus have come together to develop Innomed, a programme aimed at sharing skills, knowledge, and resources to boost innovation. The initiative has recently received support from the ITEMAS platform.
Nimble Diagnostics has been awarded a €2.5 million grant from EIC Accelerator, a funding programme of the European Innovation Council and SMEs Executive Agency (EISMEA). This spin-off from the Germans Trias i Pujol Research Institute (IGTP), the Polytechnic University of Catalonia - BarcelonaTech (UPC) and the University of Barcelona (UB), is among the 47 selected companies from 15 countries, chosen from a pool of 648 proposals.
On 23 October, the "Translational research and innovation through EATRIS" workshop was held at IGTP. The purpose of this event was to discuss the advances and perspectives of EATRIS both in Spain and in Europe, highlighting the research and innovation activity of the IGTP.
The first urine test that detects kidney fibrosis as an alternative to kidney biopsies, an initiative from the IVECAT group, and a project applying artificial intelligence to rapidly categorise stroke patients and enhance their recovery chances, from the Neurovascular Research group, are two of the fifteen projects from Catalan research centres selected within the 2023 call of the new CaixaImpulse Healthcare Innovation programme.
